TORONTO—An analysis of gene-expression patterns in women with overactive bladder (OAB) may point the way to possible new biomarkers for the condition.

SAN FRANCISCO—Increasing levels of C-reactive protein (CRP) are associated with increasing odds of overactive bladder (OAB), according to a population-based study of men and women.

Percutaneous tibial nerve stimulation (PTNS) is safe and effective for treating overactive bladder (OAB) symptoms, a recent study shows.

The associated cost is a potential reason for undertreatment.

Only 24.4% of patients aged 45 years and older take drugs for the condition, according to researchers.

Study findings at 12 months showed prolonged significant improvements in objective urinary parameters.

Solifenacin-treated patients experienced less dry mouth than those taking oxybutynin immediate release.

Percutaneous tibial nerve stimulation may be considered an alternative treatment for overactive bladder (OAB), researchers reported in the Journal of Urology (2009;182:1055-1061).

Uroplasty, Inc., a medical device company with headquarters in Minnetonka, Minn., has received a patent for its Urgent PC Neuromodulation System and stimulation methods for treating overactive bladder (OAB).

Researchers have reported encouraging results from a small study examining intravesical instillation of a botulinum toxin/dimethyl sulfoxide (DMSO) solution as a treatment for refractory idiopathic overactive bladder (OAB).